Search

Displaying results 7311 - 7320 of 10000 in total
  1. Drug

    Pradofloxacin

    go.drugbank.com/drugs/DB11453
    ExperimentalVet approved

    It was approved by the European Commission in April 2011 for bacterial infections in dogs and cats. … Pradofloxacin is a 3rd generation fluoroquinolone antibiotic developed by Bayer HealthCare AG, Animal Health GmBH.

  2. Drug

    VB2-011

    go.drugbank.com/drugs/DB05411
    Experimental

    VB2-011 is an antibody developed as an anti-cancer treatment. According to some preclinical studies, it has a potential to inhibit tumour growth in various cancers including lymphoma and melanoma.

  3. Drug

    Iseganan

    go.drugbank.com/drugs/DB16010
    Investigational

    Iseganan is under investigation in clinical trial NCT00022373 (Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer).

  4. Drug

    Palazestrant

    go.drugbank.com/drugs/DB18971
    Investigational

    Palazestrant is under investigation in clinical trial NCT06016738 (OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer).

  5. Drug

    PT-2385

    go.drugbank.com/drugs/DB16055
    Investigational

    PT-2385 is under investigation in clinical trial NCT03108066 (PT2385 for the Treatment of Von Hippel-lindau Disease-associated Clear Cell Renal Cell Carcinoma).

  6. Drug

    Ligandrol

    go.drugbank.com/drugs/DB13934
    Investigational

    Ligandrol is an investigational selective androgen receptor modulator (SARM) for treatment of conditions such as muscle wasting and osteoporosis.

  7. Drug

    ART5803

    go.drugbank.com/drugs/DB18379
    Investigational

    ART5803 is a humanized one-armed monoclonal antibody with a high affinity for the NMDA receptor.

  8. Drug

    Rugonersen

    go.drugbank.com/drugs/DB18662
    Investigational

    Rugonersen is a locked nucleic acid antisense oligonucleotide under investigation for the treatment of Angelman Syndrome.

  9. Drug

    E1v1.11

    go.drugbank.com/drugs/DB18363
    Experimental

    E1v1.11 is an antisense oligonucleotide targeting the _SMN2_ gene which is under investigation for the treatment of spinal muscular atrophy (SMA).[L48196]

  10. Drug

    Cicletanine

    go.drugbank.com/drugs/DB12766
    Investigational

    Cicletanine is under investigation for the treatment of Diabetes, Hypokalemia, Hyponatremia, and Arterial Hypertension.